Unique ID issued by UMIN | UMIN000059351 |
---|---|
Receipt number | R000067880 |
Scientific Title | Effect of Imidazole Dipeptide Supplementation on Lipid Metabolism During Aerobic Exercise |
Date of disclosure of the study information | 2025/10/09 |
Last modified on | 2025/10/09 11:04:36 |
Effect of Imidazole Dipeptide Supplementation on Lipid Metabolism During Aerobic Exercise
Effect of Imidazole Dipeptide Supplementation on Lipid Metabolism During Aerobic Exercise in Collegiate Rugby Players
Effect of Imidazole Dipeptide Supplementation on Lipid Metabolism During Aerobic Exercise
Effect of Imidazole Dipeptide Supplementation on Lipid Metabolism During Exercise
Japan |
healthy individuals
Adult |
Others
NO
The study examines the effects of four-week continuous imidazole dipeptide intake on lipid metabolism during aerobic exercise and on changes in oxidative stress markers before and after exercise in male university students who belong to the university rugby club.
Others
The study is designed as a double-blind, controlled trial. Prior to the intervention, participants will undergo measurement of maximal oxygen uptake (VO2max). Before and after imidazole dipeptide supplementation, a 40-minute cycling exercise at 65% VO2max will be performed. During exercise, respiratory gas parameters and heart rate will be continuously monitored to evaluate changes in lipid metabolism. Body composition, and oxidative stress markers in venous blood samples also will be measuredbefore and after exercise.
Exploratory
Pragmatic
Not applicable
lipid metabolism
body composition, oxidative stress markers
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
NO
No need to know
2
Treatment
Food |
Participants will consume 2.0 g of imidazole dipeptides or placebo daily for four weeks.
Participants will consume 2.0 g of imidazole dipeptides or placebo daily for four weeks.
18 | years-old | <= |
25 | years-old | >= |
Male
1. Male university students aged 18 to 25.
2. No history of major injury or surgery within the past six months.
3. Deemed safe to participate by the physician based on self-reported medical history and medication use.
1. History of cardiovascular, respiratory, or metabolic diseases
2. Allergies to supplement ingredients (e.g., chicken-derived protein, beta-alanine)
3. Current use of substances listed on the 2025 WADA Prohibited List
30
1st name | Tomoko |
Middle name | |
Last name | Kaburagi |
Daito Bunka University
Faculty of Sports and Health Sciences
355-8501
Iwadono 560, Higashimatsuyama, Saitama
09054465497
t-kabu@ic.daito.ac.jp
1st name | Tomoko |
Middle name | |
Last name | Kaburagi |
Daito Bunka University
Faculty of Sports and Health Sciences
355-8681
Iwadono 560, Higashimatsuyama, Saitama
0493-31-1552
t-kabu@ic.daito.ac.jp
Daito Bunka University
Tomoko Kaburagi
Daito Bunka University
Other
TOKAI BUSSAN Co.,LTD.
Office of Research Promotion, Daito Bunka University
1-9-1 Takashimadaira, Itabashi-ku, Tokyo
03-5399-7830
kenkyu@jm.daito.ac.jp
YES
DHR25-015-1
Daito Bunka University Ethics Review Committee for Life Sciences and Medical Research Involving Human Subjects
2025 | Year | 10 | Month | 09 | Day |
Unpublished
Preinitiation
2025 | Year | 06 | Month | 23 | Day |
2025 | Year | 07 | Month | 25 | Day |
2025 | Year | 09 | Month | 22 | Day |
2025 | Year | 12 | Month | 10 | Day |
2026 | Year | 05 | Month | 31 | Day |
2025 | Year | 10 | Month | 09 | Day |
2025 | Year | 10 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067880